547 related articles for article (PubMed ID: 23230309)
1. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis.
Yu L; Ruifrok WP; Meissner M; Bos EM; van Goor H; Sanjabi B; van der Harst P; Pitt B; Goldstein IJ; Koerts JA; van Veldhuisen DJ; Bank RA; van Gilst WH; Silljé HH; de Boer RA
Circ Heart Fail; 2013 Jan; 6(1):107-17. PubMed ID: 23230309
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodeling.
Weisberg AD; Albornoz F; Griffin JP; Crandall DL; Elokdah H; Fogo AB; Vaughan DE; Brown NJ
Arterioscler Thromb Vasc Biol; 2005 Feb; 25(2):365-71. PubMed ID: 15576638
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Galectin-3 Pathway Prevents Isoproterenol-Induced Left Ventricular Dysfunction and Fibrosis in Mice.
Vergaro G; Prud'homme M; Fazal L; Merval R; Passino C; Emdin M; Samuel JL; Cohen Solal A; Delcayre C
Hypertension; 2016 Mar; 67(3):606-12. PubMed ID: 26781273
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological inhibition of galectin-3 protects against hypertensive nephropathy.
Frenay AR; Yu L; van der Velde AR; Vreeswijk-Baudoin I; López-Andrés N; van Goor H; Silljé HH; Ruifrok WP; de Boer RA
Am J Physiol Renal Physiol; 2015 Mar; 308(5):F500-9. PubMed ID: 25503732
[TBL] [Abstract][Full Text] [Related]
5. Connective tissue growth factor inhibition attenuates left ventricular remodeling and dysfunction in pressure overload-induced heart failure.
Szabó Z; Magga J; Alakoski T; Ulvila J; Piuhola J; Vainio L; Kivirikko KI; Vuolteenaho O; Ruskoaho H; Lipson KE; Signore P; Kerkelä R
Hypertension; 2014 Jun; 63(6):1235-40. PubMed ID: 24688123
[TBL] [Abstract][Full Text] [Related]
6. Chymase inhibition prevents cardiac fibrosis and improves diastolic dysfunction in the progression of heart failure.
Matsumoto T; Wada A; Tsutamoto T; Ohnishi M; Isono T; Kinoshita M
Circulation; 2003 May; 107(20):2555-8. PubMed ID: 12742989
[TBL] [Abstract][Full Text] [Related]
7. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction.
Sharma UC; Pokharel S; van Brakel TJ; van Berlo JH; Cleutjens JP; Schroen B; André S; Crijns HJ; Gabius HJ; Maessen J; Pinto YM
Circulation; 2004 Nov; 110(19):3121-8. PubMed ID: 15520318
[TBL] [Abstract][Full Text] [Related]
8. p38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat.
See F; Thomas W; Way K; Tzanidis A; Kompa A; Lewis D; Itescu S; Krum H
J Am Coll Cardiol; 2004 Oct; 44(8):1679-89. PubMed ID: 15489104
[TBL] [Abstract][Full Text] [Related]
9. The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload.
Meems LM; Cannon MV; Mahmud H; Voors AA; van Gilst WH; Silljé HH; Ruifrok WP; de Boer RA
J Steroid Biochem Mol Biol; 2012 Nov; 132(3-5):282-9. PubMed ID: 22800987
[TBL] [Abstract][Full Text] [Related]
10. Effect of a cleavage-resistant collagen mutation on left ventricular remodeling.
Lindsey ML; Yoshioka J; MacGillivray C; Muangman S; Gannon J; Verghese A; Aikawa M; Libby P; Krane SM; Lee RT
Circ Res; 2003 Aug; 93(3):238-45. PubMed ID: 12855673
[TBL] [Abstract][Full Text] [Related]
11. Reduction of heart failure by pharmacological inhibition or gene deletion of protein tyrosine phosphatase 1B.
Gomez E; Vercauteren M; Kurtz B; Ouvrard-Pascaud A; Mulder P; Henry JP; Besnier M; Waget A; Hooft Van Huijsduijnen R; Tremblay ML; Burcelin R; Thuillez C; Richard V
J Mol Cell Cardiol; 2012 Jun; 52(6):1257-64. PubMed ID: 22446161
[TBL] [Abstract][Full Text] [Related]
12. Beta-blocker improves survival, left ventricular function, and myocardial remodeling in hypertensive rats with diastolic heart failure.
Kobayashi M; Machida N; Mitsuishi M; Yamane Y
Am J Hypertens; 2004 Dec; 17(12 Pt 1):1112-9. PubMed ID: 15607617
[TBL] [Abstract][Full Text] [Related]
13. Basigin Promotes Cardiac Fibrosis and Failure in Response to Chronic Pressure Overload in Mice.
Suzuki K; Satoh K; Ikeda S; Sunamura S; Otsuki T; Satoh T; Kikuchi N; Omura J; Kurosawa R; Nogi M; Numano K; Sugimura K; Aoki T; Tatebe S; Miyata S; Mukherjee R; Spinale FG; Kadomatsu K; Shimokawa H
Arterioscler Thromb Vasc Biol; 2016 Apr; 36(4):636-46. PubMed ID: 26916734
[TBL] [Abstract][Full Text] [Related]
14. Anti-monocyte chemoattractant protein-1 gene therapy attenuates left ventricular remodeling and failure after experimental myocardial infarction.
Hayashidani S; Tsutsui H; Shiomi T; Ikeuchi M; Matsusaka H; Suematsu N; Wen J; Egashira K; Takeshita A
Circulation; 2003 Oct; 108(17):2134-40. PubMed ID: 14517168
[TBL] [Abstract][Full Text] [Related]
15. Disruption of histamine H2 receptor slows heart failure progression through reducing myocardial apoptosis and fibrosis.
Zeng Z; Shen L; Li X; Luo T; Wei X; Zhang J; Cao S; Huang X; Fukushima Y; Bin J; Kitakaze M; Xu D; Liao Y
Clin Sci (Lond); 2014 Oct; 127(7):435-48. PubMed ID: 24655024
[TBL] [Abstract][Full Text] [Related]
16. Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice.
Heymans S; Lupu F; Terclavers S; Vanwetswinkel B; Herbert JM; Baker A; Collen D; Carmeliet P; Moons L
Am J Pathol; 2005 Jan; 166(1):15-25. PubMed ID: 15631996
[TBL] [Abstract][Full Text] [Related]
17. Celiprolol, a vasodilatory beta-blocker, inhibits pressure overload-induced cardiac hypertrophy and prevents the transition to heart failure via nitric oxide-dependent mechanisms in mice.
Liao Y; Asakura M; Takashima S; Ogai A; Asano Y; Shintani Y; Minamino T; Asanuma H; Sanada S; Kim J; Kitamura S; Tomoike H; Hori M; Kitakaze M
Circulation; 2004 Aug; 110(6):692-9. PubMed ID: 15262839
[TBL] [Abstract][Full Text] [Related]
18. Regression of cardiac hypertrophy by granulocyte colony-stimulating factor-stimulated interleukin-1β synthesis.
Szardien S; Nef HM; Voss S; Troidl C; Liebetrau C; Hoffmann J; Rauch M; Mayer K; Kimmich K; Rolf A; Rixe J; Troidl K; Kojonazarov B; Schermuly RT; Kostin S; Elsässer A; Hamm CW; Möllmann H
Eur Heart J; 2012 Mar; 33(5):595-605. PubMed ID: 22106340
[TBL] [Abstract][Full Text] [Related]
19. Myocardial Galectin-3 Expression Is Associated with Remodeling of the Pressure-Overloaded Heart and May Delay the Hypertrophic Response without Affecting Survival, Dysfunction, and Cardiac Fibrosis.
Frunza O; Russo I; Saxena A; Shinde AV; Humeres C; Hanif W; Rai V; Su Y; Frangogiannis NG
Am J Pathol; 2016 May; 186(5):1114-27. PubMed ID: 26948424
[TBL] [Abstract][Full Text] [Related]
20. Critical role of the NAD(P)H oxidase subunit p47phox for left ventricular remodeling/dysfunction and survival after myocardial infarction.
Doerries C; Grote K; Hilfiker-Kleiner D; Luchtefeld M; Schaefer A; Holland SM; Sorrentino S; Manes C; Schieffer B; Drexler H; Landmesser U
Circ Res; 2007 Mar; 100(6):894-903. PubMed ID: 17332431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
